Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

Mount Marty University will launch the region’s first Graduate Regulatory Science Program to train future leaders in the ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Purdue University's College of Pharmacy has partnered with Stony Brook University to bring the Center for Research Innovation in Biotechnology and its Clinical Drug Experience Knowledgebase to the ...

Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up ...

Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.

Concord Biotech share price rose on the back of a healthy March quarter of financial year 2025 (Q4FY25) results.

PolyActiva is taking its high-precision glaucoma implant to global trials in a test for Australia’s biotech ambitions.